Search
Aminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalThe majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply. … Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio.
Categories: Compounds used in a research, industrial, or household settingPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast
Iobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalFDA approved on September 19, 2008.
Categories: Compounds used in a research, industrial, or household settingImdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigational[L23524] In November 2021, the same indication was approved by the EMA. … [A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults. … that it is the first and only oral CGRP antagonist approved for preventative use in migraine.
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263506] It was subsequently approved by the FDA in March 2024.[L50386] … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideSulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Mixtures: AMPICILLINA E SULBACTAM IBI, AMPICILLINA E SULBACTAM IBIMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MGRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … [L53743] ITP is an autoimmune disorder characterized by low platelet count.
Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrileCysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.